Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD,

Slides:

Advertisements

Similar presentations

Glucose Metabolism Gene Expression Patterns and Tumor Uptake of 18F- Fluorodeoxyglucose After Radiation Treatment George D. Wilson, PhD, Bryan J. Thibodeau,

Advertisements

Volume 75, Issue 1, Pages (January 2012)

Pre-operative hyperfractionated radiotherapy and concurrent 5-fu/cisplatin for locally advanced esophageal cancer - the impact of 18-F-fluoro-deoxy-d-glucose.

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:

Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated Michael D. Chuong,

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy C.

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Simultaneous positron emission tomography (PET) assessment of metabolism with 18F- fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Jeffrey Bradley, MD Journal of Thoracic Oncology

Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam– Generated Neutrons Leo E. Gerweck, PhD, Peigen Huang, MD, Hsiao-Ming.

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

Vaginal Motion and Bladder and Rectal Volumes During Pelvic Intensity-Modulated Radiation Therapy After Hysterectomy Anuja Jhingran, M.D., Mohammad Salehpour,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

2-[18F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

2-[18F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer Qurrat Mehmood, MBChB., Alexander.

Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F- Fluorodeoxyglucose PET-CT Jeong Won Lee, MD, Seok-Ki Kim, MD, Ji Won Park,

Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma Amanda J. Walker, MD, Alin Chirindel, MD, Robert.

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Numb Chin Syndrome: An Ominous Sign of Lung Cancer

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Solitary Choriocarcinoma in the Lung

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non– Small-Cell Lung Cancer Neeharika Srivastava, MD, Paul A. VanderLaan,

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Axillary Mass and Hypercalcemia: The Value of a Physical Examination

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Jeffrey Bradley, MD Journal of Thoracic Oncology

Nicholas W. Choong, MD, Robert S. Hellman, MD

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability Prashant Gabani, MD, Benjamin W.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Metastatic Lung Cancer to the Pancreas

False-Positive FDG-PET and Bronchial Anthracofibrosis

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Focal Cholesterol Granuloma in the Anterior Mediastinum: [18F]-Fluoro-2-Deoxy-D- Glucose-Positron Emission Tomography and Magnetic Resonance Imaging Findings

Fig. 1.Representative images of 18F-FDG PET-CT and immunohistochemical staining for TILs. (A) Whole-body 18F-FDG PET image demonstrates increased FDG uptake.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD, Joseph Cho, BS, Gregory C. Sharp, PhD, Noah C. Choi, MD International Journal of Radiation Oncology • Biology • Physics Volume 89, Issue 1, Pages 137-144 (May 2014) DOI: 10.1016/j.ijrobp.2014.01.047 Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 1 Design of the study. Schematically shown are pretherapy scan (S1) with 50% of maximum standard uptake value of 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) uptake threshold; 10-day posttherapy (S2), 3-month posttherapy (S3), and 6-month posttherapy (S4) scans with 80% of maximum standard uptake value of FDG uptake threshold. All posttherapy scans were rigidly aligned with the pretherapy scan. Overlap of FDG uptake at S1 and each of the posttherapy uptakes within thresholds was calculated. International Journal of Radiation Oncology • Biology • Physics 2014 89, 137-144DOI: (10.1016/j.ijrobp.2014.01.047) Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 2 Representative images of a patient with pretherapy (S1) and 10-day (S2) and 3-month (S3) posttherapy 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography computed tomography (18F-FDG PET-CT). Green line indicates gross tumor volume outlined on pretherapy CT. Red lines indicate 50% of maximum standard uptake value threshold of FDG uptake on pretherapy PET (S1) and 80% of maximum standard uptake value threshold of FDG uptake on posttherapy PETl (S2,S3). A color version of this figure is available at www.redjournal.org. International Journal of Radiation Oncology • Biology • Physics 2014 89, 137-144DOI: (10.1016/j.ijrobp.2014.01.047) Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 3 Examples of heterogeneous 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) uptake distribution in 4 different tumors. Green contour indicates gross tumor volume outlined on pretherapy computed tomography. Red contour indicates 50% of maximum standard uptake value threshold of FDG uptake on pretherapy positron emission tomography. A color version of this figure is available at www.redjournal.org International Journal of Radiation Oncology • Biology • Physics 2014 89, 137-144DOI: (10.1016/j.ijrobp.2014.01.047) Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 4 Overlap fractions of the pretherapy (S1) with 3 posttherapy (S2, S3, S4) 2-deoxy-2-[18F]-fluoro-D-glucose uptakes calculated for 17 patients. Data are expressed as means ± 95% confidence intervals. International Journal of Radiation Oncology • Biology • Physics 2014 89, 137-144DOI: (10.1016/j.ijrobp.2014.01.047) Copyright © 2014 Elsevier Inc. Terms and Conditions